-
公开(公告)号：US07999005B2
公开(公告)日：2011-08-16
申请号：US12277974
申请日：2008-11-25
IPC分类号： A01N31/335
CPC分类号： A61K9/0024 , A61K31/365 , A61K31/568 , A61K45/06 , A61K2300/00
摘要： An improved weight and growth stimulant for domesticated animals such as cattle, pigs and sheep is comprised of an anabolic agent that is subcutaneously administered in the form of a dual release implant formulation. Increased gains are particularly improved when zeranol is administered in an immediate-release and controlled-release formulation which allows for a one-time dosage injection.
摘要翻译： 用于驯养动物如牛，猪和绵羊的改善的重量和生长兴奋剂由以双重释放植入物制剂的形式皮下施用的合成代谢剂组成。 当使用允许进行一次剂量注射的速释制剂和控制释放制剂中施用Zeranol时，增加的益处特别好。
-
公开(公告)号：US20090075962A1
公开(公告)日：2009-03-19
申请号：US12277974
申请日：2008-11-25
IPC分类号： A61K31/565 , A61K31/365
CPC分类号： A61K9/0024 , A61K31/365 , A61K31/568 , A61K45/06 , A61K2300/00
摘要： An improved weight and growth stimulant for domesticated animals such as cattle, pigs and sheep is comprised of an anabolic agent that is subcutaneously administered in the form of a dual release implant formulation. Increased gains are particularly improved when zeranol is administered in an immediate-release and controlled-release formulation which allows for a one-time dosage injection.
-
公开(公告)号：US07767708B2
公开(公告)日：2010-08-03
申请号：US09431519
申请日：1999-11-01
IPC分类号： A61K31/335
CPC分类号： A61K9/0024 , A61K31/365 , A61K31/568 , A61K45/06 , A61K2300/00
摘要： An improved weight and growth stimulant for domesticated animals such as cattle, pigs and sheep is comprised of an anabolic agent that is subcutaneously administered in the form of a dual release implant formulation. Increased gains are particularly improved when zeranol is administered in an immediate-release and controlled-release formulation which allows for a one-time dosage injection.
摘要翻译： 用于驯养动物如牛，猪和绵羊的改善的重量和生长兴奋剂由以双重释放植入物制剂的形式皮下施用的合成代谢剂组成。 当使用允许进行一次剂量注射的速释制剂和控制释放制剂中施用Zeranol时，增加的益处特别好。
-
4.发明授权Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto 有权可用于治疗与之相关疾病的5-HT2A 5-羟色胺受体调节剂的组成公开(公告)号：US09034911B2
公开(公告)日：2015-05-19
申请号：US13126564
申请日：2009-10-27
申请人： Lee Alani Selvey , Marlon Carlos , Paul Maffuid , Yun Shan , William L. Betts, III , Deam Windate Given, III , Ryan M. Hart , Zezhi Jesse Shao
发明人： Lee Alani Selvey , Marlon Carlos , Paul Maffuid , Yun Shan , William L. Betts, III , Deam Windate Given, III , Ryan M. Hart , Zezhi Jesse Shao
IPC分类号： A61K31/415 , C07D231/16 , A61K9/20 , A61K9/16
CPC分类号： A61K31/415 , A61K9/1635 , A61K9/2027 , A61K9/2054 , C07D231/16
摘要： The present invention relates to certain compositions of a 5-HT2A serotonin receptor modulator and methods for their preparation. The compositions disclosed herein are useful for increasing slow wave sleep, improving sleep consolidation, improving sleep maintenance and improving sleep quality, and for treating insomnia and related sleep disorders, dyssomnias, parasomnias and nonrestorative sleep and the like. The compositions disclosed herein are further useful for treating platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic-related disorders and progressive multifocal leukoencephalopathy and the like.
摘要翻译： 本发明涉及5-HT2A 5-羟色胺受体调节剂的某些组合物及其制备方法。 本文公开的组合物可用于增加慢波睡眠，改善睡眠巩固，改善睡眠维持和改善睡眠质量，以及用于治疗失眠和相关的睡眠障碍，睡眠障碍，异睡眠和非恢复性睡眠等。 本文公开的组合物还可用于治疗血小板聚集，冠状动脉疾病，心肌梗塞，短暂性脑缺血发作，心绞痛，中风，心房颤动，血栓形成，哮喘或其症状，其激动或症状，行为障碍，药物诱导的精神病，兴奋性 精神病，Gilles de la Tourette综合征，躁狂症，有机或NOS精神病，精神病，精神病，急性精神分裂症，慢性精神分裂症，精神分裂症精神分裂症和相关疾病，糖尿病相关疾病和进行性多灶性脑白质病等。
-
5.发明申请MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT 审中-公开用于体重管理的5-HT2C激动剂的修饰释放剂量形式公开(公告)号：US20130315994A1
公开(公告)日：2013-11-28
申请号：US13820107
申请日：2011-08-31
申请人： Zezhi Jesse Shao , Anthony C. Blackburn , Andrew J. Grottick , Michael Morgan , Jaimie Karyn Rueter , Anna Shifrina , Scott Stirn , Libo Yang , Woo Hyun Yoon
发明人： Zezhi Jesse Shao , Anthony C. Blackburn , Andrew J. Grottick , Michael Morgan , Jaimie Karyn Rueter , Anna Shifrina , Scott Stirn , Libo Yang , Woo Hyun Yoon
CPC分类号： A61K31/55 , A23P20/12 , A61K9/0053 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/2846 , A61K9/2866 , A61K31/135 , A61K31/155 , A61K45/06 , C07D223/16 , A61K2300/00
摘要： The present invention relates to methods for weight management that utilize modified-release dosage forms comprising (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine salts and crystalline forms thereof. The present invention further relates to (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine salts, crystalline forms thereof and modified-release dosage forms comprising them.
摘要翻译： 本发明涉及使用包含（R）-8-氯-1-甲基-2,3,4,5-四氢-1H-3-苯并氮杂盐及其结晶形式的改型释放剂型的体重管理方法。 本发明还涉及（R）-8-氯-1-甲基-2,3,4,5-四氢-1H-3-苯并氮杂盐，其结晶形式和包含它们的改性释放剂型。
-
公开(公告)号：US20120029081A1
公开(公告)日：2012-02-02
申请号：US13267352
申请日：2011-10-06
申请人： Howard N. Bockbrader , Yun Hyung Cho , Steven Diaz Santiago , Majid Mahjour , Thomas Daniel Reynolds , Pushpa Ganapathi Shao , Zezhi Jesse Shao , Jiansheng Wan
发明人： Howard N. Bockbrader , Yun Hyung Cho , Steven Diaz Santiago , Majid Mahjour , Thomas Daniel Reynolds , Pushpa Ganapathi Shao , Zezhi Jesse Shao , Jiansheng Wan
CPC分类号： A61K47/32 , A61K9/0053 , A61K9/0065 , A61K9/141 , A61K9/146 , A61K9/2027 , A61K31/197 , A61K47/34 , A61K2039/542
摘要： A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.
摘要翻译： 描述了含有普瑞巴林的固体药物组合物。 该组合物包括基质形成剂和溶胀剂，并且适合于每日一次的口服给药。 示例性的基质形成剂包括聚乙酸乙烯酯和聚乙烯吡咯烷酮的混合物，示例性的溶胀剂包括聚乙烯吡咯烷酮的交联聚合物。
-
公开(公告)号：US20120232149A1
公开(公告)日：2012-09-13
申请号：US13472704
申请日：2012-05-16
申请人： Howard N. Bockbrader , Yun Hyung Cho , Steven Diaz Santiago , Majid Mahjour , Thomas Daniel Reynolds , Pushpa Ganapathi Shao , Zezhi Jesse Shao , Jiansheng Wan
发明人： Howard N. Bockbrader , Yun Hyung Cho , Steven Diaz Santiago , Majid Mahjour , Thomas Daniel Reynolds , Pushpa Ganapathi Shao , Zezhi Jesse Shao , Jiansheng Wan
IPC分类号： A61K31/195 , A61P25/08 , A61P25/02 , A61P25/18 , A61P1/00 , A61P25/22 , A61P25/24 , A61P25/00 , A61P25/20
CPC分类号： A61K47/32 , A61K9/0053 , A61K9/0065 , A61K9/141 , A61K9/146 , A61K9/2027 , A61K31/197 , A61K47/34 , A61K2039/542
摘要： A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.
摘要翻译： 描述了含有普瑞巴林的固体药物组合物。 该组合物包括基质形成剂和溶胀剂，并且适合于每日一次的口服给药。 示例性的基质形成剂包括聚乙酸乙烯酯和聚乙烯吡咯烷酮的混合物，示例性的溶胀剂包括聚乙烯吡咯烷酮的交联聚合物。
-
8.发明申请COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO 有权用于治疗与相关疾病相关的5-HT2A硒鼓调节因子的组合物公开(公告)号：US20110207791A1
公开(公告)日：2011-08-25
申请号：US13126564
申请日：2009-10-27
申请人： Lee Alani Selvey , Marlon Carlos , Paul Maffuid , Yun Shan , William L. Betts, III , Deam Windate Given, III , Ryan M. Hart , Zezhi Jesse Shao
发明人： Lee Alani Selvey , Marlon Carlos , Paul Maffuid , Yun Shan , William L. Betts, III , Deam Windate Given, III , Ryan M. Hart , Zezhi Jesse Shao
IPC分类号： A61K31/415 , A61P9/10 , A61P9/00 , A61P9/12 , A61P25/00
CPC分类号： A61K31/415 , A61K9/1635 , A61K9/2027 , A61K9/2054 , C07D231/16
摘要： The present invention relates to certain compositions of a 5-HT2A serotonin receptor modulator and methods for their preparation. The compositions disclosed herein are useful for increasing slow wave sleep, improving sleep consolidation, improving sleep maintenance and improving sleep quality, and for treating insomnia and related sleep disorders, dyssomnias, parasomnias and nonrestorative sleep and the like. The compositions disclosed herein are further useful for treating platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic-related disorders and progressive multifocal leukoencephalopathy and the like.
摘要翻译： 本发明涉及5-HT2A 5-羟色胺受体调节剂的某些组合物及其制备方法。 本文公开的组合物可用于增加慢波睡眠，改善睡眠巩固，改善睡眠维持和改善睡眠质量，以及用于治疗失眠和相关的睡眠障碍，睡眠障碍，异睡眠和非恢复性睡眠等。 本文公开的组合物还可用于治疗血小板聚集，冠状动脉疾病，心肌梗塞，短暂性脑缺血发作，心绞痛，中风，心房颤动，血栓形成，哮喘或其症状，其激动或症状，行为障碍，药物诱导的精神病，兴奋性 精神病，Gilles de la Tourette综合征，躁狂症，有机或NOS精神病，精神病，精神病，急性精神分裂症，慢性精神分裂症，精神分裂症精神分裂症和相关疾病，糖尿病相关疾病和进行性多灶性脑白质病等。
-
9.发明授权Taste masking of oral quinolone liquid preparations using ion exchange resins 有权使用离子交换树脂对口服喹诺酮液体制剂进行口味掩蔽公开(公告)号：US06514492B1
公开(公告)日：2003-02-04
申请号：US09614523
申请日：2000-07-12
申请人： Rong Gao , Zezhi Jesse Shao , Allan Chor-Lun Fan , Leonore Catherine Witchey-Lakshmanan , Daniel Charles Stewart
发明人： Rong Gao , Zezhi Jesse Shao , Allan Chor-Lun Fan , Leonore Catherine Witchey-Lakshmanan , Daniel Charles Stewart
IPC分类号： A61K3174
CPC分类号： A61K9/0095 , A61K31/74 , A61K31/785 , A61K47/32
摘要： This invention relates to the formulation of oral liquid products of quinolones or derivatives thereof using ion exchange resins, such as methacrylic acid polymer crosslinked with divinylbenzene, as the carrier, thereby eliminating the extreme bitterness of the quinolones oral liquid formulation.
摘要翻译： 本发明涉及使用离子交换树脂如二乙烯基苯交联的甲基丙烯酸聚合物作为载体制备喹诺酮或其衍生物的口服液体产品，从而消除喹诺酮口服液体制剂的极端苦味。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.03 秒)
